Literature DB >> 2210778

Production of a monoclonal antibody (K 931) to a squamous cell carcinoma associated antigen identified as the 17-1A antigen.

J J Quak1, G Van Dongen, J G Brakkee, D J Hayashida, A J Balm, G B Snow, C J Meijer.   

Abstract

During our efforts to develop monoclonal antibodies (MAbs) to tumor associated surface antigens of squamous cell carcinomas of the head and neck, monoclonal antibody K 931 was produced. The high affinity antibody (Ka 5.0 x 10(10) M-1) showed reactivity with 58 out of 62 squamous cell carcinomas of the head and neck. In contrast normal squamous epithelium as found in epidermis, oral cavity, epiglottis, pharynx, larynx and esophagus did not express the antigen. All other tested epithelial (simple and transitional) tissues did express the antigen, but non-epithelial tissues were negative. Further characterization revealed that the antigen represents the 17-1A antigen. A not earlier reported, enhanced expression of the 17-1A antigen was observed among some primary and all metastatic SCC.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2210778     DOI: 10.1089/hyb.1990.9.377

Source DB:  PubMed          Journal:  Hybridoma        ISSN: 0272-457X


  14 in total

1.  Expression of Ep-CAM in cervical squamous epithelia correlates with an increased proliferation and the disappearance of markers for terminal differentiation.

Authors:  S V Litvinov; W van Driel; C M van Rhijn; H A Bakker; H van Krieken; G J Fleuren; S O Warnaar
Journal:  Am J Pathol       Date:  1996-03       Impact factor: 4.307

2.  Cytoplasmic tail regulates the intercellular adhesion function of the epithelial cell adhesion molecule.

Authors:  M Balzar; H A Bakker; I H Briaire-de-Bruijn; G J Fleuren; S O Warnaar; S V Litvinov
Journal:  Mol Cell Biol       Date:  1998-08       Impact factor: 4.272

Review 3.  [Squamous cell carcinoma of the head and neck. Principles and current concepts of immunotherapy].

Authors:  T K Hoffmann; T L Whiteside; H Bier
Journal:  HNO       Date:  2005-03       Impact factor: 1.284

4.  Carcinoma-associated monoclonal antibodies in head and neck carcinoma. Immunohistochemistry and biodistribution of monoclonal antibodies 175F4 and 175F11.

Authors:  A J Balm; P C Hageman; C L Mulder; J Hilkens
Journal:  Eur Arch Otorhinolaryngol       Date:  1992       Impact factor: 2.503

Review 5.  Current perspectives in the use of monoclonal antibodies for detection and treatment of head and neck tumors.

Authors:  J Quak; G van Dongen
Journal:  Eur Arch Otorhinolaryngol       Date:  1994       Impact factor: 2.503

6.  Potential for targeting head and neck squamous cell carcinoma with monoclonal antibody K984.

Authors:  A H Schrijvers; M Gerretsen; M van Walsum; B J Braakhuis; J J Quak; G B Snow; G A van Dongen
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

Review 7.  Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor.

Authors:  Virginia M Platt; Francis C Szoka
Journal:  Mol Pharm       Date:  2008-06-03       Impact factor: 4.939

8.  Construction and characterization of the chimeric monoclonal antibody E48 for therapy of head and neck cancer.

Authors:  R H Brakenhoff; F B van Gog; J E Looney; M van Walsum; G B Snow; G A van Dongen
Journal:  Cancer Immunol Immunother       Date:  1995-03       Impact factor: 6.968

9.  KSA antigen Ep-CAM mediates cell-cell adhesion of pancreatic epithelial cells: morphoregulatory roles in pancreatic islet development.

Authors:  V Cirulli; L Crisa; G M Beattie; M I Mally; A D Lopez; A Fannon; A Ptasznik; L Inverardi; C Ricordi; T Deerinck; M Ellisman; R A Reisfeld; A Hayek
Journal:  J Cell Biol       Date:  1998-03-23       Impact factor: 10.539

10.  Radioimmunotherapy of human head and neck squamous cell carcinoma xenografts with 131I-labelled monoclonal antibody E48 IgG.

Authors:  M Gerretsen; A H Schrijvers; M van Walsum; B J Braakhuis; J J Quak; C J Meijer; G B Snow; G A van Dongen
Journal:  Br J Cancer       Date:  1992-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.